The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG
Open accessAbstract
BACKGROUND: Several guidelines have been reported for bone-directed treatment in women with early breast cancer (EBC) for averting fractures, particularly during aromatase inhibitor (AI) therapy. Recently, a number of studies on additional fracture related risk factors, new treatment options as well as real world studies demonstrating a much higher fracture rate than suggested by randomized clinical controlled trials (RCTs). Therefore, this updated algorithm was developed to better assess fracture risk and direct treatment as a position statement of several interdisciplinary cancer and bone societies involved in the management of AI-associated bone loss (AIBL). PATIENTS AND METHODS: A systematic literature review identified recent advances in the management of AIBL. Results with individual agents were assessed based on trial design, size, follow-up, and safety. RESULTS: Several fracture related risk factors in patients with EBC were identified. Although, the FRAX algorithm includes fracture risk factors (RF) in addition to BMD, it does not seem to adequately address the effects of AIBL. Several antiresorptive agents can prevent and treat AIBL. However, concerns regarding compliance and long-term safety remain. Overall, the evidence for fracture prevention is strongest for denosumab 60 mg s.c. every 6 months. Additionally, recent studies as well as an individual patient data meta-analysis of all available randomized trial data support additional anticancer benefits from adjuvant bisphosphonate treatment in postmenopausal women with a 34% relative risk reduction in bone metastasis and 17% relative risk decrease in breast cancer mortality that needs to be taken into account when advising on management of AIBL. CONCLUSIONS: In all patients initiating AI treatment, fracture risk should be assessed and recommendation with regard to exercise and calcium/vitamin D supplementation given. Bone-directed therapy should be given to all patients with a T-score<-2.0 or with a T-score of <-1.5 SD with one additional RF, or with ≥2 risk factors (without BMD) for the duration of AI treatment. Patients with T-score>-1.5 SD and no risk factors should be managed based on BMD loss during the first year and the local guidelines for postmenopausal osteoporosis. Compliance should be regularly assessed as well as BMD on treatment after 12 - 24 months. Furthermore, because of the decreased incidence of bone recurrence and breast cancer specific mortality, adjuvant bisphosphonates are recommended for all postmenopausal women at significant risk of disease recurrence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Correspondence - Tranexamic acid for traumatic brain injury
(2005) · London School of Economics and Political Science Theses Online (London School of Economics and Political Science) · doi:10.1016/s0140-6736 · Cited by 11,894
Professor Kanis, J. A., Melton, L. J., Christiansen, C., Johnston, C. C., & Khaltaev, N. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090802 · Cited by 3,849
Cuzick, J., Sestak, I., Baum, M., Buzdar, A., Howell, A., Dowsett, M., & Forbes, J. F. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70257-6 · Cited by 1,674
Body mass index as a predictor of fracture risk: A meta-analysis
De Laet, C., Kanis, J. A., Odén, A., Johanson, H., Johnell, O., Delmas, P., Eisman, J. A., Kroger, H., Fujiwara, S., Garnero, P., et al. (2005) · Osteoporosis International · doi:10.1007/s00198-005-1863-y · Cited by 1,622
Self-citationSmoking and fracture risk: a meta-analysis
Kanis, J. A., Johnell, O., Oden, A., Johansson, H., De Laet, C., Eisman, J. A., Fujiwara, S., Kroger, H., McCloskey, E. V., Mellstrom, D., et al. (2005) · Osteoporosis International · doi:10.1007/s00198-004-1640-3 · Cited by 999
Self-citationA meta-analysis of prior corticosteroid use and fracture risk.
Kanis, J. A., Johansson, H., Oden, A., Johnell, O., de Laet, C., Melton, L. J., Tenenhouse, A., Reeve, J., Silman, A. J., Pols, H. A., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040134 · Cited by 839
Self-citationEffects of exercise on fracture reduction in older adults: A systematic review and meta-analysis
Kemmler, W., Häberle, L., & von Stengel, S. (2013) · Osteoporosis International · doi:10.1007/s00198-012-2248-7 · Cited by 174
Cited by
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., Zackrisson, S., & Senkus, E. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz173 · Cited by 2,214
UK clinical guideline for the prevention and treatment of osteoporosis
Gregson, C. L., Armstrong, D. J., Bowden, J., Cooper, C., Edwards, J., Gittoes, N. J. L., Harvey, N., Kanis, J., Leyland, S., Low, R., et al. (2022) · Archives of Osteoporosis · doi:10.1007/s11657-022-01061-5 · Cited by 593
Self-citationBone health in cancer: ESMO Clinical Practice Guidelines
Coleman, R., Hadji, P., Body, J.-J., Santini, D., Chow, E., Terpos, E., Oudard, S., Bruland, Ø., Flamen, P., Kurth, A., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.019 · Cited by 549
Self-citationBone metastasis: mechanisms, therapies, and biomarkers
Clézardin, P., Coleman, R., Puppo, M., Ottewell, P., Bonnelye, E., Paycha, F., Confavreux, C. B., & Holen, I. (2021) · Physiological Reviews · doi:10.1152/physrev.00012.2019 · Cited by 416
Self-citationEbeling, P. R., Nguyen, H. H., Aleksova, J., Vincent, A. J., Wong, P., & Milat, F. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab028 · Cited by 338
Metadata
- Authors
- Hadji, P., Aapro, M. S., Body, J.-J., Gnant, M., Brandi, M. L., Reginster, J. Y., Zillikens, M. C., Glüer, C.-C., de Villiers, T., Baber, R., Roodman, G. D., Cooper, C., Langdahl, B., Palacios, S., Kanis, J., Al-Daghri, N., Nogues, X., Eriksen, E. F., Kurth, A., Rizzoli, R., & Coleman, R. E.
- Venue
- Journal of Bone Oncology
- Publisher
- Elsevier BV
- Published
- 2017-06
- Volume
- 7
- Pages
- 1-12
- ISSN
- 2212-1366 (ISSN-L)
- 2212-1374
- OpenAlex
- W2598259575
- Cited by
- 277
- References
- 7
- FWCI
- 10.77
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG. https://app.cochat.ai/papers/10.1016/j.jbo.2017.03.001
- The paper
- Hadji, P., Aapro, M. S., Body, J.-J., Gnant, M., Brandi, M. L., Reginster, J. Y., Zillikens, M. C., Glüer, C.-C., de Villiers, T., Baber, R., Roodman, G. D., Cooper, C., Langdahl, B., Palacios, S., Kanis, J., Al-Daghri, N., Nogues, X., Eriksen, E. F., Kurth, A., . . . Coleman, R. E. (2017). Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG. Journal of Bone Oncology. https://doi.org/10.1016/j.jbo.2017.03.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.